Nav: Home

A common nerve protein elevated in aggressive neuroblastomas

October 12, 2016

WASHINGTON - A protein produced by nerve cells appears to be elevated in the blood of those with an aggressive form of neuroblastoma. The finding, published online October 12 in the American Journal of Pathology, could potentially lead to a prognostic test for the disease or be used to monitor its progress.

Neuroblastoma is a pediatric cancer with varying types, ranging from spontaneously regressing to untreatable fatal tumors. Consequently, treatment strategies vary significantly between patients, encompassing different approaches including observation alone or intensive chemo- and radiotherapy.

"Given the severe late effects of anti-cancer treatment administered to infants and children, proper disease stratification is of utmost importance for neuroblastoma patients," explains Joanna Kitlinska, PhD, associate professor in the department of biochemistry and molecular & cellular biology at Georgetown University Medical Center.

Because of their neuronal origin, neuroblastomas synthesize and release neuropeptide Y (NPY), a small protein normally secreted from mature nerves. In previous research, Kitlinska and her colleagues have shown that NPY, acting via its Y2 and Y5 receptors (Y2R and Y5R), is crucial for maintaining neuroblastoma growth and protecting the tumors from chemotherapy.

"To confirm the clinical relevance of our earlier work and assess NPY and its receptors as potential prognostic factors, we performed clinical study on tissue samples and serum from 87 neuroblastoma patients," Kitlinska explains.

"We have found that NPY is released from aggressive neuroblastoma tumors into the blood, which results in its elevated serum concentrations. These high systemic levels of NPY are associated with several adverse prognostic factors for neuroblastoma and worse survival of neuroblastoma patients. "

She adds that high NPY release is a strong marker of metastatic disease, while the Y5R is present preferentially in invasive neuroblastoma cells. Also, patients with elevated NPY at diagnosis were more likely to have a disease relapse in the future.

"These results support the previously described crucial role for NPY in neuroblastoma biology, and suggest its contribution to the disease dissemination and resistance to therapy. Thus, our study validates the NPY system as a potential therapeutic target and potential prognostic marker for neuroblastoma," she says.

"In contrast to complex genetic analyses currently utilized to assess risk of the disease, the measurement of NPY levels in blood can be converted to a readily available analytical test. Using such easily accessible clinical material may also allow for minimally invasive longitudinal monitoring of the disease progression," Kitlinska explains.

"If confirmed by further prospective studies, this finding may have a significant impact on the clinical management of patients with neuroblastoma," she concludes.
-end-
In addition to Kitlinska, authors include Chris Albanese, Susana Galli, Chao Yang, Jessica Tsuei, Jason Tilan, Emily Trinh, Sung-Hyeok Hong, Olga C. Rodriguez, Hongkun Wang and Yi-Chien Lee of Georgetown; Arlene Naranjo and Collin Van Ryn from the University of Florida Children's Oncology Group; and Ewa Izycka-Swieszewska of Medical University of Gda?sk, Poland.

Kitlinska and her co-authors report having no personal financial interests related to the study.

Samples of neuroblastic tumors were obtained from Children's Oncology Group, which also provided statistical support for the study (Naranjo and Van Ryn). The association of high NPY and Y5R expression with metastatic phenotype of the tumor cells was confirmed in an animal model of neuroblastoma, in collaboration with the Georgetown Lombardi Comprehensive Cancer Center Preclinical Imaging Research Laboratory (Albanese and Rodriguez).

The study was supported by grants from the National Institutes of Health (UL1TR000101 1RO1CA123211, 1R03CA178809, 1R01CA197964, 1R21CA198698, U10CA180899 and P30-CA051008.)

About Georgetown University Medical CenterGeorgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health. Connect with GUMC on Facebook (Facebook.com/GUMCUpdate), Twitter (@gumedcenter) and Instagram (@gumedcenter).

Georgetown University Medical Center

Related Neuroblastoma Articles:

A step forward in the struggle against neuroblastoma, a type of childhood cancer
A protein called CD44 makes it possible to identify the population of mother cells that are responsible for the aggressive nature and low survival rate of neuroblastoma, a type of childhood cancer that mainly affects children of two and three years old.
More children survive neuroblastoma
Both the survival rate and the incidence of neuroblastoma have increased in the last decennia in the Netherlands, as was shown by a study from the Princess Máxima Center.
TTUHSC researchers publish preclinical data on new drug combination to treat neuroblastoma
Neuroblastoma, the most common cancer outside of the brain in infants and young children, often fails to respond to therapy.
New gene found for a deadly childhood cancer offers possibility of targeted drug therapy
Neuroblastoma accounts for 15% of total childhood cancer deaths and survival rates of high-risk neuroblastoma patients is 50%.
Proton therapy shows efficacy, low toxicity in large cohort of children with high-risk neuroblastoma
Researchers from Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania analyzed the largest cohort to date of pediatric patients with high-risk neuroblastoma treated with proton radiation therapy (PRT), finding both that proton therapy was effective at reducing tumors and demonstrated minimal toxicity to surrounding organs.
Antibody-drug conjugate shows efficacy against cell surface protein in neuroblastoma
Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing cancer cells.
Scientists discover potential way to treat and prevent cancer in children (neuroblastoma)
The MYCN oncogene is known to be a key cause of a number of deadly solid tumour cancers, including neuroblastoma which claims more lives of children under 5 than any other cancer.
A mechanistic approach to neuroblastoma prognosis and risk
A new study reveals key molecular indicators that could help doctors select the best form of treatment for patients with neuroblastoma -- the most common type of cancer in infants.
Drug combination makes cancer disappear in mice with neuroblastoma
Researchers investigating new treatments for neuroblastoma -- one of the most common childhood cancers -- have found that a combination of two drugs made tumors disappear in mice, making it more effective than any other drugs tested in these animals.
Study finds that DFMO increases survival for children with high risk neuroblastoma
A paper published September 27 in Scientific Reports shows the positive results of a phase II clinical trial using the oral medication DFMO to prevent relapse in children with High Risk Neuroblastoma (HRNB).
More Neuroblastoma News and Neuroblastoma Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.